Antibiotics for asthma attacks: masking uncertainty
Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Simon Couillard(Université de Sherbrooke)
Cited by 10
Related Papers
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
|Thorax|2021|169
Survival analysis of patients on maintenance hemodialysis
|Indian Journal of Nephrology|2014|100
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
|The Lancet Respiratory Medicine|2024|98